These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

505 related items for PubMed ID: 21410627

  • 21. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
    Jabbour SA, Hardy E, Sugg J, Parikh S, Study 10 Group.
    Diabetes Care; 2014; 37(3):740-50. PubMed ID: 24144654
    [Abstract] [Full Text] [Related]

  • 22. Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial.
    Zang L, Liu Y, Geng J, Luo Y, Bian F, Lv X, Yang J, Liu J, Peng Y, Li Y, Sun Y, Bosch-Traberg H, Mu Y.
    Diabetes Obes Metab; 2016 Aug; 18(8):803-11. PubMed ID: 27060930
    [Abstract] [Full Text] [Related]

  • 23. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide.
    Wysham C, Bergenstal R, Malloy J, Yan P, Walsh B, Malone J, Taylor K.
    Diabet Med; 2011 Jun; 28(6):705-14. PubMed ID: 21434995
    [Abstract] [Full Text] [Related]

  • 24. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes.
    Ferrannini E, Berk A, Hantel S, Pinnetti S, Hach T, Woerle HJ, Broedl UC.
    Diabetes Care; 2013 Dec; 36(12):4015-21. PubMed ID: 24186878
    [Abstract] [Full Text] [Related]

  • 25. Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes.
    Dobs AS, Goldstein BJ, Aschner P, Horton ES, Umpierrez GE, Duran L, Hill JS, Chen Y, Golm GT, Langdon RB, Williams-Herman DE, Kaufman KD, Amatruda JM, Ferreira JC.
    J Diabetes; 2013 Mar; 5(1):68-79. PubMed ID: 22742523
    [Abstract] [Full Text] [Related]

  • 26. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
    Forst T, Guthrie R, Goldenberg R, Yee J, Vijapurkar U, Meininger G, Stein P.
    Diabetes Obes Metab; 2014 May; 16(5):467-77. PubMed ID: 24528605
    [Abstract] [Full Text] [Related]

  • 27. Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients.
    Derosa G, Carbone A, Franzetti I, Querci F, Fogari E, Bianchi L, Bonaventura A, Romano D, Cicero AF, Maffioli P.
    Diabetes Res Clin Pract; 2012 Oct; 98(1):51-60. PubMed ID: 22682949
    [Abstract] [Full Text] [Related]

  • 28. A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sitagliptin.
    Violante R, Oliveira JH, Yoon KH, Reed VA, Yu MB, Bachmann OP, Lüdemann J, Chan JY.
    Diabet Med; 2012 Nov; 29(11):e417-24. PubMed ID: 22375612
    [Abstract] [Full Text] [Related]

  • 29. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.
    Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE, Sitagliptin 036 Study Group.
    Diabetes Care; 2007 Aug; 30(8):1979-87. PubMed ID: 17485570
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).
    Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z.
    Diabetes Care; 2014 Aug; 37(8):2149-58. PubMed ID: 24742660
    [Abstract] [Full Text] [Related]

  • 31. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial.
    Pratley R, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Garber A, Thomsen AB, Hartvig H, Davies M, 1860-LIRA-DPP-4 Study Group.
    Int J Clin Pract; 2011 Apr; 65(4):397-407. PubMed ID: 21355967
    [Abstract] [Full Text] [Related]

  • 32. Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial.
    Hollander P, Raslova K, Skjøth TV, Råstam J, Liutkus JF.
    Diabetes Obes Metab; 2011 Mar; 13(3):268-75. PubMed ID: 21205123
    [Abstract] [Full Text] [Related]

  • 33. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
    Bergenstal RM, Wysham C, Macconell L, Malloy J, Walsh B, Yan P, Wilhelm K, Malone J, Porter LE, DURATION-2 Study Group.
    Lancet; 2010 Aug 07; 376(9739):431-9. PubMed ID: 20580422
    [Abstract] [Full Text] [Related]

  • 34. The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes.
    Yang W, Guan Y, Shentu Y, Li Z, Johnson-Levonas AO, Engel SS, Kaufman KD, Goldstein BJ, Alba M.
    J Diabetes; 2012 Sep 07; 4(3):227-37. PubMed ID: 22672586
    [Abstract] [Full Text] [Related]

  • 35. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P, Sitagliptin Study 035 Group.
    Diabetes Obes Metab; 2007 Sep 07; 9(5):733-45. PubMed ID: 17593236
    [Abstract] [Full Text] [Related]

  • 36. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes.
    Yoon KH, Shockey GR, Teng R, Golm GT, Thakkar PR, Meehan AG, Williams-Herman DE, Kaufman KD, Amatruda JM, Steinberg H.
    Int J Clin Pract; 2011 Feb 07; 65(2):154-64. PubMed ID: 21235696
    [Abstract] [Full Text] [Related]

  • 37. Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes.
    Fonseca V, Staels B, Morgan JD, Shentu Y, Golm GT, Johnson-Levonas AO, Kaufman KD, Goldstein BJ, Steinberg H.
    J Diabetes Complications; 2013 Feb 07; 27(2):177-83. PubMed ID: 23116881
    [Abstract] [Full Text] [Related]

  • 38. Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin.
    Amin NB, Wang X, Jain SM, Lee DS, Nucci G, Rusnak JM.
    Diabetes Obes Metab; 2015 Jun 07; 17(6):591-598. PubMed ID: 25754396
    [Abstract] [Full Text] [Related]

  • 39. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.
    Ahrén B, Johnson SL, Stewart M, Cirkel DT, Yang F, Perry C, Feinglos MN, HARMONY 3 Study Group.
    Diabetes Care; 2014 Aug 07; 37(8):2141-8. PubMed ID: 24898304
    [Abstract] [Full Text] [Related]

  • 40. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study.
    Seck T, Nauck M, Sheng D, Sunga S, Davies MJ, Stein PP, Kaufman KD, Amatruda JM, Sitagliptin Study 024 Group.
    Int J Clin Pract; 2010 Apr 07; 64(5):562-76. PubMed ID: 20456211
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.